Table 1.

Vaccine formulations in development for non-Hodgkin lymphomas.

Vaccine formulationStarting materialProduction timeTarget tumor antigen(s)Phase of clinical developmentPotential applicabilityReferences
Idiotype-based FNA or core biopsy  Tumor-specific Well-defined  B-cell malignancies  
    Id protein-KLH  > 2 mo  Phase 3  10,15–17,23,30  
    Id protein-DC  > 2 mo  Phase 2  22  
    DNA  < 1 mo  Phase 1  37,38,50  
Membrane proteoliposome Excisional biopsy < 1 mo Multiple Undefined Phase 1 Multiple malignancies 39,40  
Tumor-cell based Excisional biopsy  Multiple Undefined  Multiple malignancies  
    GM-CSF transduced  < 1 mo  Phase 2  41  
    CD40 activated  < 1 mo  Phase 1  42  
    HSP-96  < 1 mo  Phase 1  45  
Vaccine formulationStarting materialProduction timeTarget tumor antigen(s)Phase of clinical developmentPotential applicabilityReferences
Idiotype-based FNA or core biopsy  Tumor-specific Well-defined  B-cell malignancies  
    Id protein-KLH  > 2 mo  Phase 3  10,15–17,23,30  
    Id protein-DC  > 2 mo  Phase 2  22  
    DNA  < 1 mo  Phase 1  37,38,50  
Membrane proteoliposome Excisional biopsy < 1 mo Multiple Undefined Phase 1 Multiple malignancies 39,40  
Tumor-cell based Excisional biopsy  Multiple Undefined  Multiple malignancies  
    GM-CSF transduced  < 1 mo  Phase 2  41  
    CD40 activated  < 1 mo  Phase 1  42  
    HSP-96  < 1 mo  Phase 1  45  
View Large